*ST萬方(000638.SZ):為優化疫苗板塊佈局 擬增持萬方百奧14.094%的股權
格隆匯1月7日丨*ST萬方(000638.SZ)公佈,為優化疫苗板塊佈局,公司於2022年1月6日與寧波麗辛投資合夥企業(有限合夥)(“寧波麗辛”)簽訂了《股權轉讓合同》,公司擬使用自有資金或自籌資金收購寧波麗辛持有的公司控股子公司吉林萬方百奧生物科技有限公司(“萬方百奧”)14.0940%的股權。根據協議約定,按照2元/股的價格,標的股權的轉讓總價款為人民幣2100萬元。萬方百奧系公司持股36.91%的控股子公司,此次交易完成後,公司將持有萬方百奧51.0067%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.